Foghorn Therapeutics to Participate in Two Upcoming Investor Conferences in September

Rhea-AI Summary

Foghorn Therapeutics (Nasdaq: FHTX), a clinical-stage biotech company, announced its participation in two upcoming investor conferences in September 2024. The company will attend the Wells Fargo Healthcare Conference on September 4 for one-on-one meetings. At the Morgan Stanley 22nd Annual Global Healthcare Conference on September 6, Foghorn's President and CEO, Adrian Gottschalk, will give a presentation at 8:30 a.m. EDT and participate in one-on-one meetings.

Foghorn is pioneering a new class of medicines that correct abnormal gene expression to treat serious diseases, with an initial focus on oncology. Their Gene Traffic Control® platform and broad pipeline aim to transform lives across various diseases. A webcast of the Morgan Stanley presentation will be available on the company's website for 30 days.

News Market Reaction – FHTX

-4.40%

-4.40% Session move

In the trading session that priced this news, FHTX declined 4.40%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

CAMBRIDGE, Mass., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Foghorn^® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced management's participation in the 2024 Wells Fargo Healthcare Conference and presentation at the Morgan Stanley 22^nd Annual Global Healthcare Conference. With an initial focus in oncology, Foghorn’s Gene Traffic Control^® platform and resulting broad pipeline have the potential to transform the lives of people suffering from a wide spectrum of diseases.

2024 Wells Fargo Healthcare Conference

• Management will participate in one-on-one meetings on Wednesday, September 4
  

Morgan Stanley 22^nd Annual Global Healthcare Conference

• Presentation: Friday, September 6, 2024, at 8:30 a.m. EDT at the Marriott Marquis, New York, New York
• Foghorn Presenter: Adrian Gottschalk, President and Chief Executive Officer
• Please find a link to the webcast here
• Management will also participate in one-on-one meetings on Friday, September 6

A webcast of the presentation can be accessed under “Events & Presentations” in the Investors section of the Company’s website, www.foghorntx.com, and will be available for 30 days.

About Foghorn Therapeutics
Foghorn^® Therapeutics is discovering and developing a novel class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Through its proprietary scalable Gene Traffic Control^® platform, Foghorn is systematically studying, identifying and validating potential drug targets within the chromatin regulatory system. The Company is developing multiple product candidates in oncology. Visit our website at www.foghorntx.com for more information about the Company, and follow us on X and LinkedIn.

Contact:

Karin Hellsvik, Foghorn Therapeutics Inc. (Investors & Media)
khellsvik@foghorntx.com

FAQ

When is Foghorn Therapeutics (FHTX) participating in the Wells Fargo Healthcare Conference?

Foghorn Therapeutics (FHTX) will participate in one-on-one meetings at the Wells Fargo Healthcare Conference on Wednesday, September 4, 2024.

What is the date and time of Foghorn Therapeutics' (FHTX) presentation at the Morgan Stanley Global Healthcare Conference?

Foghorn Therapeutics (FHTX) will present at the Morgan Stanley 22nd Annual Global Healthcare Conference on Friday, September 6, 2024, at 8:30 a.m. EDT.

Who will be presenting for Foghorn Therapeutics (FHTX) at the Morgan Stanley conference?

Adrian Gottschalk, President and Chief Executive Officer of Foghorn Therapeutics (FHTX), will be presenting at the Morgan Stanley conference.

Where can investors access the webcast of Foghorn Therapeutics' (FHTX) Morgan Stanley conference presentation?

Investors can access the webcast of Foghorn Therapeutics' (FHTX) presentation under the 'Events & Presentations' section in the Investors area of the company's website, www.foghorntx.com.

What is the main focus of Foghorn Therapeutics' (FHTX) Gene Traffic Control® platform?

Foghorn Therapeutics' (FHTX) Gene Traffic Control® platform focuses on correcting abnormal gene expression to treat serious diseases, with an initial emphasis on oncology.